topics / GIP agonist

Tagged GIP agonist.

Preliminary human VK2735 (Viking) VK2735 is an investigational dual GLP-1/GIP receptor agonist from Viking Therapeutics being studied for obesity and metabolic disease. Phase 2 data are promising but it is not approved anywhere, and long-term safety is unknown.